Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks

XORTX Therapeutics

Market Cap: CA$6.5m

A late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease.

Passage Bio

Market Cap: US$24.5m

A genetic medicines company, develops gene therapies for central nervous system diseases.

Anbio Biotechnology

Market Cap: US$1.6b

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.

Exicure

Market Cap: US$26.9m

Does not have significant operations.

Financière de Tubize

Market Cap: €7.1b

Operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium.

Cizzle Biotechnology Holdings

Market Cap: UK£7.1m

Operates as a cancer diagnostics company in the United Kingdom.

Ventyx Biosciences

Market Cap: US$196.1m

A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.

Arterra Bioscience

Market Cap: €18.2m

A research-based biotech company, engages in the research and development of various ingredients and natural solutions.

Medicure

Market Cap: CA$11.5m

A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.

Dianthus Therapeutics

Market Cap: US$1.4b

A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.

InMed Pharmaceuticals

Market Cap: US$4.4m

A clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.

Vanda Pharmaceuticals

Market Cap: US$289.5m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

Protara Therapeutics

Market Cap: US$157.4m

A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.

Amylyx Pharmaceuticals

Market Cap: US$1.5b

A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

Vaxil Bio

Market Cap: CA$534.2k

A biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer.

DBV Technologies

Market Cap: €210.1m

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Propanc Biopharma

Market Cap: US$24.8m

A development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.

Bioceltix

Market Cap: zł509.2m

Engages in the development of stem cell-based biopharmaceuticals for veterinary use.

OS Therapies

Market Cap: US$70.9m

A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

Vaxcyte

Market Cap: US$4.3b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Pacira BioSciences

Market Cap: US$1.2b

Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

TME Pharma

Market Cap: €9.3m

A clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.

PExA

Market Cap: €9.6m

Develops and commercializes diagnostic products in various respiratory diseases.

Qiagen

Market Cap: US$9.8b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

Novacyt

Market Cap: €33.2m

Develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors.

Kyverna Therapeutics

Market Cap: US$278.5m

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

Bone Biologics

Market Cap: US$3.9m

A medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.

Septerna

Market Cap: US$753.9m

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

Lite Strategy

Market Cap: US$93.0m

A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.

Context Therapeutics

Market Cap: US$85.6m

A biopharmaceutical company, develops products for the treatment of solid tumors.

Lantern Pharma

Market Cap: US$49.5m

Focuses on the discovery and development of oncology drug.

Annexin Pharmaceuticals

Market Cap: SEK 197.7m

A biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases.

Sagimet Biosciences

Market Cap: US$236.8m

A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.

GH Research

Market Cap: US$862.8m

Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.

4D Molecular Therapeutics

Market Cap: US$394.2m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Physiomics

Market Cap: UK£1.5m

Provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.